Literature DB >> 16288296

AKT crystal structure and AKT-specific inhibitors.

Chandra C Kumar1, Vincent Madison.   

Abstract

AKT kinases are attractive targets for small molecule drug discovery because of their key role in tumor cell survival/proliferation and their overexpression/activation in many human cancers. This review summarizes studies that support the rationale for targeting AKT kinases in new drug discovery efforts. Structural features of AKT kinase in its inactive and active states, as determined by crystal structure analysis, are described. Recent efforts in the development and biological evaluation of small molecule inhibitors of AKT, and the challenges remaining are summarized. Inhibitors targeting the ATP binding site, PH domain and protein substrate binding site, as well as isoform selective allosteric inhibitors are reviewed. Structure-based design using PKA mutants as surrogates and computer modeling in the discovery of selective inhibitors is discussed. The issues and challenges facing the development of different classes of inhibitors as therapeutics are also discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288296     DOI: 10.1038/sj.onc.1209087

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  72 in total

Review 1.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Authors:  Margrith E Mattmann; Sydney L Stoops; Craig W Lindsley
Journal:  Expert Opin Ther Pat       Date:  2011-06-02       Impact factor: 6.674

2.  Akt determines cell fate through inhibition of the PERK-eIF2α phosphorylation pathway.

Authors:  Zineb Mounir; Jothi Latha Krishnamoorthy; Shuo Wang; Barbara Papadopoulou; Shirley Campbell; William J Muller; Maria Hatzoglou; Antonis E Koromilas
Journal:  Sci Signal       Date:  2011-09-27       Impact factor: 8.192

3.  Accurate prediction of the bound form of the Akt pleckstrin homology domain using normal mode analysis to explore structural flexibility.

Authors:  Hoang T Tran; Shuxing Zhang
Journal:  J Chem Inf Model       Date:  2011-08-25       Impact factor: 4.956

4.  Emergent decision-making in biological signal transduction networks.

Authors:  Tomás Helikar; John Konvalina; Jack Heidel; Jim A Rogers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

5.  Discovery of a novel class of AKT pleckstrin homology domain inhibitors.

Authors:  Daruka Mahadevan; Garth Powis; Eugene A Mash; Benjamin George; Vijay M Gokhale; Shuxing Zhang; Kishore Shakalya; Lei Du-Cuny; Margareta Berggren; M Ahad Ali; Umasish Jana; Nathan Ihle; Sylvestor Moses; Chloe Franklin; Satya Narayan; Nikhil Shirahatti; Emmanuelle J Meuillet
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

6.  Interaction of human biliverdin reductase with Akt/protein kinase B and phosphatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: a novel mechanism of Akt activation.

Authors:  Tihomir Miralem; Nicole Lerner-Marmarosh; Peter E M Gibbs; Jermaine L Jenkins; Chelsea Heimiller; Mahin D Maines
Journal:  FASEB J       Date:  2016-05-10       Impact factor: 5.191

Review 7.  Drugs for allosteric sites on receptors.

Authors:  Cody J Wenthur; Patrick R Gentry; Thomas P Mathews; Craig W Lindsley
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-02       Impact factor: 13.820

Review 8.  Protein kinases and phosphatases as therapeutic targets in cancer.

Authors:  Juan-José Ventura; Angel R Nebreda
Journal:  Clin Transl Oncol       Date:  2006-03       Impact factor: 3.405

Review 9.  Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer.

Authors:  Kanchan Sonkar; Vinay Ayyappan; Caitlin M Tressler; Oluwatobi Adelaja; Ruoqing Cai; Menglin Cheng; Kristine Glunde
Journal:  NMR Biomed       Date:  2019-06-11       Impact factor: 4.044

10.  Serine 474 phosphorylation is essential for maximal Akt2 kinase activity in adipocytes.

Authors:  Alison L Kearney; Kristen C Cooke; Dougall M Norris; Armella Zadoorian; James R Krycer; Daniel J Fazakerley; James G Burchfield; David E James
Journal:  J Biol Chem       Date:  2019-09-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.